ADMA, cardiovascular disease and diabetes

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Biochemistry

Background:

• Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase.
• Elevated ADMA levels are associated with adverse cardiovascular risk profiles.
• ADMA is increasingly recognized as a significant risk marker for cardiovascular events.

Purpose of the Study:

• To review the existing literature on the relationship between ADMA and cardiovascular disease (CVD).
• To explore the role of ADMA as both a risk marker and a potential causative factor in CVD.
• To examine the specific association between ADMA, CVD, and diabetes mellitus.

Main Methods:

• Literature review of studies investigating ADMA and cardiovascular outcomes.
• Analysis of patient cohorts with varying cardiovascular risk profiles.
• Synthesis of evidence regarding ADMA's role in cardiovascular pathophysiology.

Main Results:

• Numerous studies identify ADMA as an independent predictor of cardiovascular events.
• Elevated ADMA concentrations are consistently found in patients with high cardiovascular risk.
• Evidence suggests ADMA may contribute causally to the development of cardiovascular disease.

Conclusions:

• ADMA is a validated biomarker for predicting future cardiovascular events.
• The role of ADMA extends beyond a risk marker, potentially acting as a causative agent in CVD.
• Understanding the ADMA-CVD-diabetes link is crucial for risk stratification and management.